Essex Bio-Technology Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Essex Bio-Technology is de winst gegroeid met een gemiddeld jaarlijks percentage van 0.01%, terwijl de Biotechs industrie de winst jaarlijks groeide met 31.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 8.5% per jaar. Het rendement op eigen vermogen van Essex Bio-Technology is 13%, en het heeft een nettomarge van 16.2%.

Belangrijke informatie

0.005%

Groei van de winst

0.3%

Groei van de winst per aandeel

Biotechs Groei van de industrie	11.0%
Inkomstengroei	8.5%
Rendement op eigen vermogen	13.0%
Nettomarge	16.2%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Oct 09

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

Aug 29

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

May 02

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Mar 30

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Jun 29

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Mar 31

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Mar 13

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Feb 15

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

Jan 25

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Jan 04

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Dec 13

Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters

Nov 23

Opbrengsten en kosten

Hoe Essex Bio-Technology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:1061 Opbrengsten, kosten en inkomsten (HKD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 24	1,619	263	1,160
31 Mar 24	1,663	269	1,195
31 Dec 23	1,707	275	1,229
30 Sep 23	1,634	266	1,161
30 Jun 23	1,561	256	1,093
31 Mar 23	1,439	241	1,003
31 Dec 22	1,318	225	914
30 Sep 22	1,437	274	950
30 Jun 22	1,556	323	987
31 Mar 22	1,597	334	988
31 Dec 21	1,638	346	990
30 Sep 21	1,515	339	908
30 Jun 21	1,392	332	825
31 Mar 21	1,185	275	707
31 Dec 20	978	219	588
30 Sep 20	1,000	221	589
30 Jun 20	1,022	222	589
31 Mar 20	1,151	262	652
31 Dec 19	1,279	303	715
30 Sep 19	1,238	282	715
30 Jun 19	1,197	262	716
31 Mar 19	1,187	246	717
31 Dec 18	1,176	231	719
30 Sep 18	1,100	210	673
30 Jun 18	1,023	189	628
31 Mar 18	961	178	592
31 Dec 17	900	167	556
30 Sep 17	874	159	528
30 Jun 17	849	151	500
31 Mar 17	813	144	479
31 Dec 16	776	136	458
30 Sep 16	740	126	446
30 Jun 16	705	115	434
31 Mar 16	679	110	419
31 Dec 15	654	105	403
30 Sep 15	627	101	379
30 Jun 15	600	96	355
31 Mar 15	559	86	334
31 Dec 14	518	75	314
30 Sep 14	466	67	295
30 Jun 14	413	59	275
31 Mar 14	380	57	256
31 Dec 13	347	55	238

Kwaliteitswinsten: 1061 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (16.2%) 1061 } zijn lager dan vorig jaar (16.4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 1061 is de afgelopen 5 jaar met 0.01% per jaar gegroeid.

Versnelling van de groei: De winstgroei van 1061 over het afgelopen jaar ( 2.7% ) overtreft het 5-jarig gemiddelde ( 0.01% per jaar).

Winst versus industrie: De winstgroei 1061 over het afgelopen jaar ( 2.7% ) overtrof de Biotechs -sector 5.5%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 13% ) van 1061 wordt als laag beschouwd.

Essex Bio-Technology Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2024 earnings released: EPS: HK$0.28 (vs HK$0.30 in 1H 2023)

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Full year 2023 earnings: EPS misses analyst expectations

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Recent updates

Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement

Investor sentiment improves as stock rises 19%

First half dividend increased to HK$0.06

Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's

First half 2024 earnings released: EPS: HK$0.28 (vs HK$0.30 in 1H 2023)

Essex Bio-Technology Limited to Report First Half, 2024 Results on Aug 26, 2024

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.045 per share

Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement

Now 21% overvalued

Now 22% overvalued

Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024

Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)

Essex Bio-Technology Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Essex Bio-Technology Limited to Report Fiscal Year 2023 Results on Mar 18, 2024

Investor sentiment deteriorates as stock falls 16%

Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.045 per share at 2.0% yield

First half 2023 earnings released: EPS: HK$0.30 (vs HK$0.24 in 1H 2022)

Essex Bio-Technology Limited to Report First Half, 2023 Results on Aug 16, 2023

Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative (Wet) Age-Related Macular Degeneration

Less than half of directors are independent

Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.025 per share at 1.8% yield

Now 21% undervalued after recent price drop

Essex Bio-Technology Limited Completes First Patient First Dose in the United States in an International Multi-Centre Phase 3 Clinical Study

Essex Bio-Technology Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Price target decreased to HK$6.00

Less than half of directors are independent

Consensus revenue estimates fall by 18%

Upcoming dividend of HK$0.04 per share

Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04

First half 2022 earnings released: EPS: HK$0.24 (vs HK$0.28 in 1H 2021)

Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on September 21, 2022

Essex Bio-Technology Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021

Price target increased to HK$7.00

Less than half of directors are independent

Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.04 per share

First half 2021 earnings released: EPS HK$0.28 (vs HK$0.085 in 1H 2020)

Investor sentiment improved over the past week

Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Essex Bio-Technology Limited Approves Final Dividend for the Year Ended December 31, 2021 at the Annual General Meeting held on May 12, 2021

Upcoming dividend of HK$0.05 per share

Is Essex Bio-Technology (HKG:1061) A Risky Investment?

Essex Bio-Technology Limited Announces Dividend for the Year Ended December 31, 2020, Payable on 1 June 2021

If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today

Essex Bio-Technology Limited, Annual General Meeting, May 12, 2021

Full year 2020 earnings released: EPS HK$0.38 (vs HK$0.52 in FY 2019)

Essex Bio-Technology Limited to Report Fiscal Year 2020 Results on Mar 12, 2021

Investor sentiment improved over the past week

Essex Bio-Technology Limited Announces Positive Outcome of U.S. FDA Second Phase 3 Clinical Trial in Dry Eye Disease

New 90-day high: HK$4.85

How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?

Investor sentiment improved over the past week

New 90-day high: HK$4.40

Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?

New 90-day low: HK$3.74

Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?